Table 5.

Effect of individual EIAEDs on the pharmacokinetics of CPT-11 and its metabolites

		Low CPT-11 dose (100/125 mg/m2)				High CPT-11 dose (250/300 mg/m2)
		None (n = 4)	CBZ (n = 4)	DPH (n = 16)	PB (n = 3)	None (n = 9)	CBZ (n = 7)	DPH (n = 12)	PB (n = 2)
CPT-11	Cmax	1820 ± 1330	780 ± 450	2440 ± 3500	1190 ± 600	2490 ± 650	2780 ± 1340	1920 ± 590	2030 ± 280
	AUC	7600 ± 2300	4000 ± 1840	6040 ± 4390	6190 ± 810	16,000 ± 4100	13,100 ± 5000	9100 ± 2200	13,500 ± 2500
	Cl	12.2 ± 2.0	27.6 ± 10.7	21.4 ± 9.8	14.3 ± 2.0	14.3 ± 4.4	19.6 ± 7.2	26.0 ± 6.3	15.9 ± 2.9
	t1/2	6.2 ± 0.9	4.9 ± 1.0	5.4 ± 0.6	5.0 ± 0.6	6.0 ± 0.9	4.8 ± 0.5	5.3 ± 0.6	5.1 ± 0.4
APC	Cmax	145 ± 90	93 ± 43	154 ± 87	247 ± 120	387 ± 92	365 ± 99	408 ± 122	484 ± 193
	AUC	1830 ± 1320	990 ± 590	1570 ± 860	2880 ± 1150	4820 ± 1280	4060 ± 1050	4490 ± 1890	5680 ± 2090
	t1/2	7.3 ± 2.0	5.7 ± 0.9	5.7 ± 0.9	5.4 ± 0.2	6.5 ± 1.9	5.3 ± 0.5	5.8 ± 1.1	6.5 ± 1.1
SN-38	Cmax	18.4 ± 2.8	11.7 ± 3.5	11.9 ± 5.4	12.0 ± 0.9	34.9 ± 23.9	19.2 ± 5.6	14.6 ± 4.8	16.6 ± 1.6
	AUC	154 ± 45	73 ± 38	60 ± 30	100 ± 14	322 ± 198	169 ± 86	106 ± 44	157 ± 2
	t1/2	17.4 ± 3.3	9.4 ± 2.3	15.6 ± 13.1	10.5 ± 2.4	16.7 ± 5.8	10.4 ± 3.0	12.0 ± 3.4	10.8 ± 0.6
SN-38G	Cmax	57.0 ± 29.7	49.7 ± 11.7	55.8 ± 24.0	63.7 ± 13.2	117.7 ± 59.8	97.7 ± 15.3	91.6 ± 20.0	91.8 ± 19.0
	AUC	623 ± 330	330 ± 164	396 ± 201	622 ± 193	1310 ± 690	875 ± 248	631 ± 152	876 ± 127
	t1/2	15.9 ± 7.8	8.6 ± 2.3	9.3 ± 2.0	10.2 ± 2.9	14.1 ± 3.0	8.7 ± 1.7	10.3 ± 3.8	9.8 ± 1.6